The story of Sildenafil presents a challenging picture for investors. While the initial introduction generated significant gains, the expiration of its patent opened the floodgates to off-brand versions, dramatically diminishing revenue. This poses a unique risk for drug manufacturers banking on related blockbuster products, suggesting that a blind

The history of Viagra, and its developer copyright, presents a intriguing case study for investors. Originally a blockbuster drug, producing billions in sales , its intellectual property lapse created a wave of knock-off medications, significantly impacting its market share . While some businesses may try to capitalize on related treatments , the c